Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal

LLY•2026-07-16

Lilly to acquire AtaiBeckley

July 16 (Reuters) - Eli Lilly said on Thursday it would acquire psychedelic drug developer AtaiBeckley for up to $3.8 billion, entering the race to develop psychedelic treatments for depression and other mental health disorders.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal

Lilly to acquire AtaiBeckley

Related News

Iran, US escalate in Gulf but release of American signals path to climb down

Bridgeline Digital signs multi-year HawkSearch upgrade deal with online retailer through 2029

Sendas says plan to open 25 in-store pharmacies in 2026 aligns with strategy disclosures

Citizens Financial rises after Q2 profit jump

US June retail sales data